The heterogeneous impact of targeted therapy on the prognosis of stage III/IV colorectal cancer patients with different subtypes of TP53 mutations

Jie Chen, Xiaona Chang, Xinyi Li, Jiaying Liu, Na Wang, Ying Wu, Liduan Zheng, Xiu NieCancer 2023 · DOI

TL;DR

This study investigates how different subtypes of TP53 mutations in colorectal cancer (CRC) patients influence the effectiveness of targeted therapies. The findings reveal that targeted therapy significantly improves overall survival (OS) for patients with specific TP53 mutations (gain-of-function or known loss-of-function), but not for others, highlighting the need for personalized treatment strategies.

What Problem Does This Paper Address?

Colorectal cancer (CRC) remains a significant global health challenge, characterized by considerable heterogeneity in patient responses to treatment. While molecular profiling has advanced our understanding, the precise impact of specific gene mutations on treatment efficacy, particularly for targeted therapies, is not fully elucidated. The TP53 gene, a critical tumor suppressor, is frequently mutated in CRC, and these mutations are known to influence cancer progression and treatment resistance. However, TP53 mutations are not monolithic; they can be classified into different functional subtypes (e.g., gain-of-function vs. loss-of-function). This study aims to address the gap in understanding how these distinct TP53 mutation subtypes specifically affect the prognosis of stage III/IV CRC patients undergoing comprehensive treatment, especially when targeted therapies are involved.

Methods

The researchers conducted a retrospective cohort study using data from the electronic medical records of Union Hospital. They analyzed data from 286 patients with stage III/IV primary CRC who had undergone next-generation sequencing (NGS) to detect TP53 mutations.

Key methodological aspects include:

  • TP53 Mutation Classification: Two distinct methods were employed to classify TP53 mutations:
  • Gain-of-Function (GOF) vs. Non-GOF: Missense mutations in the DNA-binding domain were classified as GOF, while mutations in other regions, in-frame deletions/insertions, and truncating mutations were classified as non-GOF.
  • Loss-of-Function (LOF) Classification: Mutations were categorized as "known LOF" or "likely LOF" based on annotations in the OncoKB database, requiring sufficient experimental evidence for classification.
  • Survival Analysis:
    • Kaplan-Meier plots and log-rank tests were used for initial survival comparisons.
  • Parametric survival analysis (Weibull distribution) was performed for multivariate analysis, adjusting for several covariates (sex, onset, KRAS mutation, sidedness, stage, and surgery) to determine the independent impact of targeted therapy.
  • Outcomes Measured: The primary outcome was overall survival (OS), and the secondary outcome was progression-free survival (PFS).

Datasets

The study utilized a dataset of 286 patients with stage III/IV primary colorectal cancer from the electronic medical record system of Union Hospital, Huazhong University of Science and Technology. This dataset was collected between January 2019 and August 2022. No new benchmarks were introduced; the study relied on existing patient data.

Key Insights and Ideas

  • TP53 Mutation Subtypes Matter for Targeted Therapy: The most significant insight is that the impact of targeted therapy on CRC patient prognosis is not uniform but is heavily influenced by the specific subtype of TP53 mutation. This moves beyond simply knowing if TP53 is mutated.
  • Differential Benefit for GOF/Known LOF: Patients with TP53 gain-of-function (GOF) mutations or known loss-of-function (LOF) mutations appear to derive a significant survival benefit from targeted therapy. This suggests these specific mutations might sensitize tumors to certain targeted agents.
  • Limited Benefit for Non-GOF/Likely LOF: Conversely, patients with TP53 non-GOF or likely LOF mutations did not show a statistically significant improvement in overall survival with targeted therapy. This implies that these mutation types may not confer sensitivity or could even be associated with resistance.
  • Heterogeneity is Key: The study underscores the profound heterogeneity within TP53 mutations and its implications for treatment response, reinforcing the need for precision medicine approaches.

Key Results

  • Overall Survival (OS) Benefit:
    • Receiving targeted therapy was associated with better OS in patients with TP53 GOF mutations (HR 0.40, 95% CI [0.21, 0.76], p=0.005).
  • It also predicted better OS in patients with known LOF mutations (HR 0.21, 95% CI [0.07, 0.60], p=0.002).
  • However, there was no significant impact of targeted therapy on OS for patients with TP53 non-GOF mutations (HR 1.68, 95% CI [0.50, 5.63], p=0.403) or likely LOF mutations (HR 0.90, 95% CI [0.34, 2.39], p=0.837).
  • Progression-Free Survival (PFS): Receiving targeted therapy was associated with poorer PFS regardless of TP53 mutation status. This is an interesting counterpoint to the OS findings and warrants further investigation.
  • Patient Cohort: The study included 286 patients, with 166 (58.04%) receiving targeted therapy.

Limitations and Future Work

The authors acknowledge several limitations:

  • Sample Size: The study's sample size, while substantial for this specific sub-analysis, is noted as potentially limiting generalizability, and selective bias may exist.
  • TP53 Classification Ambiguity: The lack of universally agreed-upon classification criteria for TP53 mutations means that potential intragroup heterogeneity could still influence results.
  • PFS vs. OS Discrepancy: The finding that targeted therapy improved OS but worsened PFS is a notable inconsistency that requires further exploration. The authors suggest this might be due to a higher proportion of stage IV patients (more prone to progression) receiving targeted therapy, or financial factors influencing treatment choices.

Future work should focus on:

  • Investigating Specific Mechanisms: Further research is needed to understand the specific biological functions of different TP53 mutation subtypes and how they mediate differential responses to targeted therapies.
  • Refining Classification: Developing more precise and universally accepted methods for classifying TP53 mutations based on their functional impact will be crucial.
  • Exploring PFS Findings: Deeper investigation into why targeted therapy might be associated with poorer PFS despite better OS is warranted.
  • Broader Patient Populations: Expanding studies to larger and more diverse patient populations will enhance the robustness and applicability of these findings.

Summary updated

Abstract

Receiving targeted therapy had a heterogeneous impact on the prognosis of CRC patients harboring different TP53 mutations. These results provide promising value for future personalized treatment and precision medicine.
BibTeX
@inproceedings{chen2023heterogeneous,
  author = {Jie Chen and Xiaona Chang and Xinyi Li and Jiaying Liu and Na Wang and Ying Wu and Liduan Zheng and Xiu Nie},
  title = {{The heterogeneous impact of targeted therapy on the prognosis of stage III/IV colorectal cancer patients with different subtypes of TP53 mutations}},
  booktitle = {Cancer},
  year = {2023},
  doi = {10.1002/cam4.6766},
}
Figure